{"id":925608,"date":"2026-01-08T17:35:41","date_gmt":"2026-01-08T22:35:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tilray-brands-delivers-record-q2-fiscal-2026-net-revenue-of-218-million-moves-to-net-cash-position-and-reaffirms-full-year-adjusted-ebitda-guidance\/"},"modified":"2026-01-08T17:35:41","modified_gmt":"2026-01-08T22:35:41","slug":"tilray-brands-delivers-record-q2-fiscal-2026-net-revenue-of-218-million-moves-to-net-cash-position-and-reaffirms-full-year-adjusted-ebitda-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tilray-brands-delivers-record-q2-fiscal-2026-net-revenue-of-218-million-moves-to-net-cash-position-and-reaffirms-full-year-adjusted-ebitda-guidance\/","title":{"rendered":"Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance"},"content":{"rendered":"
\n

\n International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6%<\/strong>\n <\/p>\n

\n Tilray Pharma Achieves Record Quarterly Revenue<\/strong>\n <\/p>\n

\n U.S. Federal Cannabis Rescheduling Expected to Unlock New Market Opportunity for Tilray Medical Expansion into the U.S.<\/strong>\n <\/p>\n

\n Strong Financial Position with $292 Million in Cash and Marketable Securities<\/strong>
\n
\n 1<\/strong>
\n <\/sup>
\n and ~$30 Million Net Cash<\/strong>\n <\/p>\n

NEW YORK and LONDON and LEAMINGTON, Ontario, Jan. 08, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (\u201cTilray\u201d, \u201cour\u201d, \u201cwe\u201d or the \u201cCompany\u201d) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today reported financial results for its second fiscal quarter ended November 30, 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.<\/p>\n

Irwin D. Simon, Chairman and Chief Executive Officer, commented, “We achieved another record quarter with net revenue reaching $218 million, a result of disciplined execution within our diversified portfolio spanning cannabis, beverage, wellness and distribution sectors. Our business model supports scalability, adaptability in challenging markets, and long-term value creation, as demonstrated by our ability to perform while reinforcing our core operations. The quarter concluded with a strong balance sheet and ample liquidity, highlighting our prudent financial management and affording us flexibility for selective investment in strategic growth initiatives. As we continue expanding our operations and pursuing our priorities, we remain committed to achieving sustainable profitability and enhancing long-term shareholder value.”<\/p>\n

Mr. Simon, continued, \u201cWe believe federal rescheduling would mark an important advancement for medical cannabis in the United States, paving the way for more research, wider physician involvement, and better patient access. Tilray has invested for years in developing the infrastructure, expertise, and discipline needed to operate successfully in tightly regulated medical markets worldwide. As the U.S. regulatory landscape progresses, Tilray is prepared to leverage its experience to play a key role in building a responsible, research-oriented national medical cannabis industry. With a dedicated team and platform already in place with Tilray Medical U.S., we intend to leverage the infrastructure, expertise and know-how developed in conjunction with Tilray Medical\u2019s expected $150 million global medical cannabis business and our $300 million Tilray Pharma medical distribution platform in order to rollout our repeatable medical model and expand upon our current research, as well as initiating new FDA trials and partnerships for product development.\u201d<\/p>\n

_________________________
1<\/sup>Cash and marketable securities and net (debt) cash are non-GAAP financial measures. See <\/em>\u201cUse of Non-GAAP Measures<\/em>\u201d\u00a0below for additional discussion regarding these non-GAAP measures <\/em>and for a reconciliation of this Non-GAAP Measure to our most comparable GAAP measure<\/em><\/sub>.<\/sub>\u00a0<\/em><\/p>\n

\n Financial Highlights <\/strong>
\n
\n All comparisons made to the prior year period<\/em>
\n \n <\/p>\n